ORLANDO, Fla.--(BUSINESS WIRE)--Admera Health (www.admerahealth.com), an advanced molecular diagnostics company focused on personalized medicine, announced the launch of its much–anticipated genetic testing panel for inherited cardiovascular diseases at the annual meeting of the American Heart Association being held this week in Orlando, Florida.
The CardioGxOneTM panel is a comprehensive Next Generation Sequencing (NGS) based molecular test for inherited cardiovascular diseases. Developed as a joint venture between Admera Health and Health in Code, the test detects genomic variations in 213 genes related to familial cardiovascular diseases. The test is designed to detect the genetic causes of sudden death in young individuals and athletes, such as cardiomyopathies, Long QT and Marfan syndrome. CardioGxOneTM combines the genetic and clinical information of more than 85,000 individuals from a proprietary database with a comprehensive interpretive report that is reviewed by specialized cardiology geneticists. The CardioGxOneTM provides cardiologists and other physician specialists with clear genetic interpretation for risk assessment and disease diagnosis.
Zeil Rosenberg, M.D., Admera Health’s VP for Medical Affairs, stated, “The launch of CardioGxOneTM allows cardiologists to pinpoint genetic risk of disease for a wide variety of serious cardiac conditions related to Sudden Cardiac Death risk. Launch of the test also marks another milestone in Admera Health’s portfolio expansion to meet the expressed needs of cardiologists and their patients.”
Lorenzo Monserrat, M.D., Health in Code’s founder/CEO further commented: “The report and the genetic data interpretation separate the test from many others available in the market.”
About Admera Health
Admera Health is an advanced molecular diagnostics company focused on personalized medicine and non-invasive cancer testing. Dedicated to developing cutting-edge diagnostics that span the continuum of care, Admera Health will fulfill unmet medical needs with cost-effective tests and accurate analysis to guide patient care. Utilizing next generation sequencing technologies and advanced bioinformatics, Admera Health seeks to redefine disease screening, diagnosis, treatment, monitoring, and management through its innovative, personalized solutions. It is our mission to deliver transformative, valuable solutions for patients, physicians, payers, and clinical researchers. We are committed to improving the health and well-being of our global community through the direct delivery of personalized, medically actionable laboratory testing results.
About Health in Code
Health in Code Inc. is a technology-based company with 10 years international experience in the genetic diagnosis of inherited cardiovascular diseases. The company's focus includes the most comprehensive clinical interpretation of genetic results based on their proprietary knowledge management systems and databases. The Health in Code multidisciplinary team consists of expert cardiologists, informatics engineers and molecular biologists.